Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 11/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.57 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972820 | 0.92 | PLK4 (0.63) | PLK4AURKBACHEFLT3CYP2C19 | |
| SCHEMBL1974030 | 0.92 | PLK4 (0.63) | PLK4AURKBACHEFLT3CYP2C19 | |
| SCHEMBL1976930 | 0.92 | PLK4 (0.63) | PLK4AURKBACHEFLT3CYP2C19 | |
| SCHEMBL1975786 | 0.92 | PLK4 (0.49) | PLK4AURKBFLT3CYP2C19TP53 | |
| SCHEMBL1973655 | 0.92 | PLK4 (0.49) | PLK4AURKBFLT3CYP2C19TP53 | |
| SCHEMBL14547305 | 0.86 | PLK4 (0.49) | PLK4AURKBACHEFLT3CYP2C19 | |
| SCHEMBL1976224 | 0.82 | PLK4 (0.46) | PLK4AURKBFLT3CYP2C19TP53 | |
| SCHEMBL1973312 | 0.82 | PLK4 (0.46) | PLK4AURKBFLT3CYP2C19TP53 | |
| SCHEMBL14547307 | 0.81 | AURKB (0.56) | PLK4AURKBFLT3CYP2C19TP53 | |
| SCHEMBL1973960 | 0.81 | PLK4 (0.54) | PLK4AURKBFLT3CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205328-B2 | Aids viricide | IRM LLC (BM) | 2007-04-17 | — | — | US | disclosed |
| US-20040152755-A1 | Oxindoles with anti-HIV activity | IRM LLC, A DELAWARE LLC (BM) | 2004-08-05 | — | — | US | disclosed |
| WO-2004037247-A1 | OXINDOLES WITH ANTI-HIV ACTIVITY | IRM LLC (BM) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152755-A1 | Oxindoles with anti-HIV activity | IDO1, API5, NFATC1 | PLK4 1823/4885AURKB 1397/4885ACHE 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.